Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.anuhpharma.com | |
Market Cap | 1,239.27 Cr. | |
Enterprise Value(EV) | 1,232.19 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 10.84 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 22.81 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 42.21 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 55.05 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 4.49 | Calculated using Price: 247.30 |
Dividend Yield | 0.81 | Period Ending 2023-03 |
No. of Shares Subscribed | 5.01 Cr. | 50,112,000 Shares |
FaceValue | 5 | |
About Anuh Pharma Ltd. | ||
Anuh Pharma incorporated in 1960, is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company is part of the SK Group, which has evolved as a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations. |
1 Day |
|
-0.22% |
1 Week |
|
+4.50% |
1 Month |
|
+0.69% |
3 Month |
|
+48.71% |
6 Month |
|
+91.33% |
1 Year |
|
+184.88% |
2 Year |
|
+151.96% |
5 Year |
|
+277.56% |
10 Year |
|
+887.23% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 23.55 | 23.44 | 15.43 | 11.38 | 14.87 | 8.75 | 16.12 | 15.11 | 15.9 | |
Return on Capital Employed (%) | 35.13 | 34.91 | 21.61 | 16.31 | 20.56 | 10.87 | 19.75 | 19.33 | 21.05 | |
Return on Assets (%) | 13.29 | 14.37 | 10.58 | 8.35 | 10.44 | 5.06 | 8.63 | 8.99 | 9.63 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 101 | 119 | 141 | 150 | 165 | 162 | 191 | 214 | 241 | 257 | |
Non Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 2 | 9 | |
Curr. Liab. | 67 | 72 | 47 | 59 | 75 | 163 | 139 | 131 | 161 | 133 | |
Minority Int. | |||||||||||
Equity & Liab. | 168 | 191 | 187 | 208 | 239 | 326 | 333 | 347 | 404 | 399 | |
Non Curr. Assets | 24 | 40 | 50 | 54 | 87 | 103 | 95 | 88 | 97 | 107 | |
Curr. Assets | 144 | 151 | 138 | 154 | 152 | 223 | 238 | 259 | 308 | 292 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 168 | 191 | 187 | 208 | 239 | 326 | 333 | 347 | 404 | 399 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 640 | |
Other Income | 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 10 | |
Total Income | 289 | 330 | 214 | 245 | 325 | 311 | 443 | 492 | 534 | 651 | |
Total Expenditure | -253 | -289 | -183 | -220 | -291 | -284 | -387 | -439 | -476 | -570 | |
PBIDT | 36 | 41 | 30 | 26 | 35 | 27 | 56 | 53 | 58 | 80 | |
Interest | -1 | -1 | -1 | 0 | -1 | -1 | -2 | -2 | -1 | 0 | |
Depreciation | -3 | -2 | -2 | -2 | -2 | -7 | -15 | -12 | -10 | -9 | |
Taxation | -10 | -12 | -8 | -7 | -9 | -5 | -10 | -9 | -11 | -17 | |
Exceptional Items | |||||||||||
PAT | 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 54 | |
Adjusted EPS | 4 | 5 | 4 | 3 | 5 | 3 | 6 | 6 | 7 | 11 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 15 | 19 | 17 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | |
Cash Fr. Inv. | -5 | -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | |
Cash Fr. Finan. | -8 | -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | |
Net Change | 2 | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 | |
Cash & Cash Eqvt | 2 | 1 | 3 | 5 | 4 | 7 | 2 | 2 | 4 | 2 |
Mon, 29 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Manan Vadhan Designation: Company Secretary and Compliance Officer EmailId: aplcs@sk1932.com Name of the Chief Financial Officer: Darshan Rampariya Designation: Chief Financial Officer EmailId: darshan.r@anuhpharma.com Date: 29/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
Wed, 24 Apr 2024
Compliances-Compliance Certificate For The Financial Ended 31St March 2024 Compliance Certificate pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 being received from RTA for the Financial Year ended 31st March 2024. |
|||||||||||||||||||||
Thu, 18 Apr 2024
Under Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Certificate dated 17th March 2024 by Sanjay Doshi and Associates Practicing Company Secretaries for the year ended 31st March 2024 under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
Thu, 02 May 2024 |
Making Lower Lows for 3 days |
Close Within 52 Week High Zone |
Making Lower Lows for 2 Days |
High Decrease in 1 Month |
High Increase in 3 Months |